勃林格殷格翰的思力华在国内上市了吗？

Is Boehringer Ingelheim’s Slivar launched in China? Boehringer Ingelheim is the world's largest privately held pharmaceutical company, with 5 R&D centers around the world and more than 8,100 R&D and medical department employees. Boehringer Ingelheim entered China in 1994, and its China headquarters is located in Shanghai. In June 2014, Respimat (tiotropium bromide), a new soft mist inhalation device developed by Boehringer Ingelheim, was officially launched in China.

Slivar is a long-acting anticholinergic drug suitable for maintenance treatment of chronic obstructive pulmonary disease (COPD). It can help adult patients with chronic obstructive pulmonary disease (COPD) breathe easier. The recommended dose for adults is to inhale once a day through the Respimat inhaler device at the same time, taking 2 puffs each time. Be careful not to overdose.

Patients also need to pay attention to the following matters when using Siliva:

1. Use is prohibited if the patient is allergic to tiotropium bromide or olodaterol or any other component of this medicine, or is allergic to atropine or related substances, such as ipratropine or oxytropine.

2. Patients with asthma (Respimat should not be used to treat asthma), heart disease, epilepsy, hypertension, thyrotoxicosis, diabetes, aneurysm, diabetes, severe liver damage, kidney damage, planned surgery, prostate problems or difficulty urinating, narrow-angle glaucoma and other diseases should consult the relevant physician before taking the medication and use the medication with caution.

3. Avoid Slihua medicine getting into your eyes. If you accidentally get it, please rinse it with plenty of water immediately.

4. If serious adverse reactions occur during treatment, you need to contact your doctor in time. Do not take medication blindly to avoid causing more serious harm to the body.

Recommended related hot articles: /newsDetail/88947.html